Current therapies for RA are aimed at inhibiting inflammatory cytokines, especially tumor necrosis factor (TNF)-α biotherapies, such as antibodies (infliximab, adalimumab) and soluble receptor (etanercept) specific for TNF. Here, TNF is linked to rheumatoid arthritis.